Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection
- PMID: 19435431
- DOI: 10.1086/599224
Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection
Abstract
Clostridium difficile infection (CDI) has become more refractory to standard therapy. We describe 4 patients with severe refractory CDI who were successfully treated with tigecycline. Symptoms improved within 1 week. No relapses were observed. This favorable outcome suggests that tigecycline might be a useful alternative for treating severe refractory CDI.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical